Symbicort in Chronic Obstruktive Pulmonary Disease
Symbicort in Chronic Obstruktive Pulmonary Disease
Under daily routine conditions and without any intervention by the sponsor regarding the selection of subjects, diagnostic procedures, therapeutic decisions (medicinal and non- medicinal therapy, dose, duration, etc.), routine assessments, the participating physicians (i.e.general practitioners and internists) are asked to document relevant data related to the budesonide/formoterole therapy in patients with COPD.
Inclusion Criteria:
Exclusion Criteria: